PRKCG and cancer: Here, we use biochemical, cellular, and in silico approaches to understand how disease-associated variants of a conserved arginine in the C1A domain of PKCβII, R42H (cancer), and in the equivalent position in PKCγ, R42P (SCA14), have opposing functional mechanisms.